El ticagrelor muestra beneficios en la función microvascular coronaria luego de un IAMSEST

Secondary Prevention with P2Y12 Inhibitors: How Consolidated Is This Long Term Alternative vs. Aspirin?

Secondary prevention with P2Y12 inhibitors vs aspirin monotherapy in CAD patients Antiaggregation therapy plays a central role at long term to prevent new cardiovascular events in atherosclerosis patients.  After repeat myocardial infarction (MI) or stroke, prognosis can vary considerably. Even though the current guidelines prefer aspirin as the first choice for secondary prevention over P2Y12<a href="https://solaci.org/en/2023/07/13/secondary-prevention-with-p2y12-inhibitors-how-consolidated-is-this-long-term-alternative-vs-aspirin/" title="Read more" >...</a>

P2Y12 Inhibitor Monotherapy vs Aspirin: Results of a Network Meta-Analysis

Revascularization and antiaggregation guidelines have typically recommended aspirin (AAS) as first choice for secondary prevention of cardiovascular events after DES stenting. However, these past few years this strategy has been called into question, seeing as studies have shown the superiority of P2Y12 inhibitor monotherapy (IP2Y12) with clopidogrel or ticagrelor. There is little data comparing both<a href="https://solaci.org/en/2022/12/05/p2y12-inhibitor-monotherapy-vs-aspirin-results-of-a-network-meta-analysis/" title="Read more" >...</a>

¿Llegó el momento de replantear a la aspirina como la elección en prevención secundaria de MACE?

Should Aspirin Be the Standard of Secondary Prevention of MACE?

Much has been published recently on short term dual antiplatelet therapy (DAPT) both in acute (ACS) and chronic coronary syndrome (CCS) as well as safety of P2Y12 inhibitor monotherapy. When discussing secondary prevention in patients with established coronary artery disease, aspirin (ASA) has been the preferred drug for the prevention of new atherothrombotic events.  This<a href="https://solaci.org/en/2022/04/27/should-aspirin-be-the-standard-of-secondary-prevention-of-mace/" title="Read more" >...</a>

ARTE: ¿AsEl fin de la aspirina para los pacientes anticoagulados que reciben angioplastiapirina o aspirina más clopidogrel post TAVI?

HOST-EXAM: The Study that Challenges Aspirin as Long-Term Antiplatelet Therapy

The HOST-EXAM study (which was prospective, randomized, and open-label, with the participation of 37 Korean sites) was specifically designed to determine the role of aspirin as the long-term antiplatelet therapy of choice after angioplasty with current drug-eluting stents. To this end, the study compared aspirin head-to-head with clopidogrel. Over the course of four years, 5438 patients (mean<a href="https://solaci.org/en/2021/09/10/host-exam-the-study-that-challenges-aspirin-as-long-term-antiplatelet-therapy/" title="Read more" >...</a>

The Role of Aspirin after the TWILIGHT-ACS

This analysis corroborates the potential benefit of ticagrelor monotherapy following a short period of dual antiaggregation (DAPT) in patients with acute coronary syndrome (ACS). This benefit consists of a significant bleeding reduction (3.6% vs. 7.6%, P < 0.001), without compromising ischemic events (4.3% vs. 4.4%, P = 0.84). The latter, however, could be seen as<a href="https://solaci.org/en/2021/08/10/the-role-of-aspirin-after-the-twilight-acs/" title="Read more" >...</a>

Aspirina o clopidogrel post TAVI: Guías y estudios llenos de contradicciones

Post TAVR Aspirin vs. Clopidogrel: Conflicting Findings and Guidelines

One month ago we shared a meta-analysis stating aspirin (ASA) as the best antiplatelet following TAVR vs. 3 to 6 dual antiplatelet therapy suggested by guidelines.  At that time, guideline recommendations appeared obsolete. Several studies had started to support ASA monotherapy as the best antiaggregation scheme after TAVR. However, in the light of this new<a href="https://solaci.org/en/2021/06/04/post-tavr-aspirin-vs-clopidogrel-conflicting-findings-and-guidelines/" title="Read more" >...</a>

ACC 2021 | ADAPTABLE: Bajas dosis de aspirina son iguales de efectivas y con muy bajo riesgo de sangrado

ACC 2021 | ADAPTABLE: Low Doses of Aspirin Are Equally Effective and Present Lower Bleeding Risk

Patients diagnosed with cardiovascular disease taking aspirin as secondary prevention can take lower doses and achieve the same efficacy level as those taking 325 mg. According to the ADAPTABLE study, presented at the American College of Cardiology (ACC) 2021 Congress and simultaneously published in the New England Journal of Medicine (NEJM), both schemes were associated with<a href="https://solaci.org/en/2021/05/18/acc-2021-adaptable-low-doses-of-aspirin-are-equally-effective-and-present-lower-bleeding-risk/" title="Read more" >...</a>

AHA 2020 | POLYPILL: Una sola pastilla más aspirina para tratar todo

AHA 2020 | POLYPILL: One Pill Plus Aspirin to Treat Everything

Using only one compressed tablet or pill with a fixed combination of statins, angiotensin-converting enzyme inhibitors, beta-blockers, and diuretics significantly lowered cardiovascular risk in a large population without previous events (primary prevention). However, it presented an intermediate risk of cardiovascular disease onset. The TIPS-3 (The International Polycap Study 3) study had a 2-by-2-by-2 factorial design,<a href="https://solaci.org/en/2020/11/18/aha-2020-polypill-one-pill-plus-aspirin-to-treat-everything/" title="Read more" >...</a>

Angioplasty in Aspirin-Free Stable Patients with Prasugrel: Innovation Continues

Potent P2Y12 receptor inhibitors, such as prasugrel and ticagrelor, have been tested mainly in a setting of acute coronary syndromes. There is little evidence on stable patients, particularly for prasugrel. Designing a study with that purpose seemed challenging enough, but adding aspirin discontinuation in patients without a particularly high bleeding risk took this research to<a href="https://solaci.org/en/2020/11/10/angioplasty-in-aspirin-free-stable-patients-with-prasugrel-innovation-continues/" title="Read more" >...</a>

Can Aspirin Use Be Interrupted After Angioplasty?

Aspirin discontinuation 1 to 3 months after angioplasty with continued P2Y12 inhibitor therapy reduces the bleeding risk without an increase in thrombotic events. This is also the case for patients admitted with acute coronary syndrome. Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor has been shown to reduce the risk of major events compared with<a href="https://solaci.org/en/2020/09/01/can-aspirin-use-be-interrupted-after-angioplasty/" title="Read more" >...</a>